Pharsight

NOVARTIS PATENTS FACING OPPOSITIONS

Top patents of NOVARTIS facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP2959894B1 12 Oct, 2022 S1p receptor modulators for treating multiple sclerosis Jun, 2027 25
EP3294283B1 08 Mar, 2023 Sacubitril-valsartan dosage regimen for treating heart failure May, 2036 16
EP2228064B1 11 Dec, 2019 Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist May, 2025 10
EP3351246B8 18 Sep, 2019 Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis Feb, 2022 10
EP3342411B1 21 Aug, 2019 Rapamycin derivative for treating pancreas cancer Feb, 2022 10
EP3038654B1 30 Oct, 2019 New use Aug, 2034 9
EP2269603B1 20 May, 2015 Treatment of breast tumors with a rapamycin derivative in combination with exemestane Feb, 2022 9
EP2340828B1 15 Jul, 2020 Pharmaceutical combinations of an angiotensin receptor antagonist and a nep inhibitor Nov, 2026 8
EP3103448B1 03 Jul, 2019 Pharmaceutical compositions comprising an s1p modulator Sep, 2027 7
EP3143995B1 05 Dec, 2018 Rapamycin derivative for the treatment of lung cancer Feb, 2022 7
EP2563906B1 08 Nov, 2017 Process for cultivation of cho cells Apr, 2031 7
EP3067043B1 30 Nov, 2022 Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor Nov, 2028 6
EP3777834B1 16 Feb, 2022 Syringe May, 2033 6
EP3685826B1 03 Nov, 2021 Syringe Jan, 2033 6
EP3366283B1 01 Sep, 2021 Direct compression formulation and process Jan, 2025 6
EP2887961B1 28 Apr, 2021 Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033 6
EP3330370B1 24 Feb, 2021 Process for cultivation of cho cells Apr, 2031 6
EP3033086B1 22 Sep, 2021 Combination therapy for the treatment of cancer Aug, 2034 5
EP2563903B1 21 Aug, 2019 Improved cell culture medium Apr, 2031 5
EP2784084B2 04 Oct, 2023 Antagonist antibodies to IL-17A/F heterologous polypeptides Jun, 2024 4
EP3647783B1 21 Dec, 2022 Identifying patient response to s1p receptor modulator administration Apr, 2033 4
EP1983984B1 07 Mar, 2018 Tuberous sclerosis treatment Jan, 2027 4
EP2513134B1 06 Sep, 2017 Wash solution and method for affinity chromatography Dec, 2030 4
EP3023095B2 08 Nov, 2023 Direct compression formulation and process Jan, 2025 3
EP2964202B2 31 May, 2023 Oral formulations of deferasirox Mar, 2034 3
EP3858405B1 05 Apr, 2023 Syringe May, 2033 3
EP3119423B1 14 Dec, 2022 Treatment of cancer using chimeric antigen receptor Mar, 2035 3
EP3283058B1 16 Nov, 2022 Ribociclib tablet Apr, 2036 3
EP3345602B1 06 Apr, 2022 Rapamycin derivative for treating solid tumours Feb, 2022 3
EP3656373B1 16 Feb, 2022 Syringe Jan, 2033 3
EP2892535B1 22 Sep, 2021 Method of adjuvant cancer treatment Aug, 2033 3
EP3679922B1 28 Jul, 2021 Syringe May, 2033 3
EP3381444B1 19 May, 2021 Syringe Jan, 2033 3
EP3536310B1 28 Apr, 2021 Syringe May, 2033 3
EP3453387B1 03 Jun, 2020 Dosage regimen for a s1p receptor agonist Dec, 2029 3
EP3111954B1 03 Apr, 2019 Methods of treating ankylosing spondylitis using anti-il-17 antibodies Nov, 2031 3
EP2608784B1 19 Sep, 2018 Treatment or prevention of heart failure in a mammal receiving anti-coagulant therapy Aug, 2031 3
EP3805248B1 18 Jan, 2023 Process for concentration of antibodies and therapeutic products thereof Sep, 2025 2
EP3560498B1 17 Aug, 2022 Combination comprising an mek inhibitor and a b-raf inhibitor Oct, 2030 2
EP3541387B1 21 Apr, 2021 Dose and regimen for hdm2-p53 interaction inhibitors Nov, 2037 2
EP2654736B1 01 Jul, 2020 Novel pharmaceutical composition Dec, 2031 2
EP3127427B1 08 Jan, 2020 Methods of administration of thrombopoietin agonist compounds May, 2030 2
EP3409274B1 20 Nov, 2019 Dosage regimen for a s1p receptor agonist Dec, 2029 2
EP2488033B1 12 Jun, 2019 Combination comprising an MEK inhibitor and a B-raf inhibitor Oct, 2030 2
EP2869813B1 21 Nov, 2018 Syringe Jan, 2033 2
EP3121171B1 15 Aug, 2018 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine Dec, 2031 2
EP2567709B1 27 Dec, 2017 Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) Oct, 2028 2
EP3124018B1 20 Dec, 2017 Oral formulations of deferasirox Mar, 2034 2
EP2420223B1 19 Jul, 2017 Aqueous pharmaceutical compositions containing borate-polyol complexes Mar, 2029 2
EP2651918B1 12 Jul, 2017 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine Dec, 2031 2
EP2308466B1 31 May, 2017 Aqueous pharmaceutical compositions containing borate-polyol complexes Mar, 2029 2
EP2214642B1 03 May, 2017 Topical composition Oct, 2028 2
EP2762140B1 22 Mar, 2017 Treatment of solid brain tumours with a rapamycin derivative Feb, 2022 2
EP3618875B1 05 Apr, 2023 Combination therapy comprising a raf inhibitor and trametinib Apr, 2038 1
EP3738585B1 14 Dec, 2022 Direct compression formulation and process Jan, 2025 1
EP2307457B2 22 Jun, 2022 Stable and soluble antibodies inhibiting tnf Jun, 2029 1
EP3407945B1 04 May, 2022 Method for measuring flow features in an inhaler, inhaler and system Jan, 2037 1
EP3157571B1 24 Nov, 2021 Fatty acids and their use in conjugation to biomolecules Jun, 2035 1
EP2971094B1 15 Sep, 2021 Biomarkers associated with brm inhibition Mar, 2034 1
EP3076969B1 01 Sep, 2021 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor Dec, 2034 1
EP2834246B1 28 Jul, 2021 Combination products with tyrosine kinase inhibitors and their use Apr, 2033 1
EP2970468B1 07 Jul, 2021 Notch2 binding molecules for treating respiratory diseases Mar, 2034 1
EP2952177B1 20 Jan, 2021 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators Oct, 2028 1
EP3172209B1 02 Dec, 2020 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Jul, 2035 1
EP3377618B1 18 Nov, 2020 Buffers for stabilization of lentiviral preparations Nov, 2036 1
EP3160463B1 21 Oct, 2020 Intermittent dosing of mdm2 inhibitor Jun, 2035 1
EP3199193B1 26 Aug, 2020 Method for measuring flow features in an inhaler, inhaler and system Jan, 2036 1
EP3489211B1 15 Jul, 2020 Improved methods for preparing squalene May, 2031 1
EP3045164B1 15 Apr, 2020 Aqueous pharmaceutical compositions containing borate-polyol complexes Jun, 2030 1
EP2820151B1 25 Mar, 2020 Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status Feb, 2033 1
EP3340990B1 25 Sep, 2019 Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer Aug, 2036 1
EP3083676B1 28 Aug, 2019 Novel eukaryotic cells and methods for recombinantly expressing a product of interest Dec, 2034 1
EP3083677B1 28 Aug, 2019 Novel eukaryotic cells and methods for recombinantly expressing a product of interest Dec, 2034 1
EP2911684B1 19 Jun, 2019 Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes Oct, 2033 1
EP3137595B1 13 Mar, 2019 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest Apr, 2035 1
EP2724728B1 17 Oct, 2018 Complexes of il-15 and il-15r alpha and uses thereof Jun, 2028 1
EP2558092B1 27 Jun, 2018 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer Apr, 2031 1
EP2925299B1 06 Jun, 2018 Novel pharmaceutical composition Nov, 2033 1
EP2934515B1 04 Apr, 2018 A pharmaceutical combination comprising binimetinib Dec, 2033 1
EP2124547B1 28 Mar, 2018 Cancer treatment method Feb, 2028 1
EP2918684B1 10 Jan, 2018 Rapid sterility microassay May, 2030 1
EP2908777B1 02 Aug, 2017 System for providing an intraocular lens having an improved depth of field Dec, 2033 1
EP2234781B1 05 Jul, 2017 Method for cast molding contact lenses Dec, 2028 1
EP2783686B1 21 Jun, 2017 Combination of a rapamycin derivative and letrozole for treating breast cancer Feb, 2022 1